• BioPark Visit (Only for Invitees)
  • Inauguration of the 16th BioAsia Convention
    Presentation of Genome Valley Excellence Award
  • Inauguration and Visit to the Exhibition
  • Welcome Reception (Only for Invitees)
  • Keynote Addresses
  • Networking Break & Visit to the Exhibition
    Track 1: Product Innovation & Development
    Participant Profile:
    • Pharma companies
    • Biotech companies
    • CROs, CMOs, CRAMs
    • Tech companies
    • Startups
    • Medical, ethical and regulatory affairs / boards
    • Policy makers
    • Academia (including research institutes) and Scientists
    Networking Break & Visit to the Exhibition
    Track 2: Product Supply
    Participant Profile :
    • Pharma companies
    • Biotech companies
    • CROs, CMOs, CRAMs
    • Tech companies
    • Startups
    • Medical, ethical and regulatory affairs / boards
    • Policy makers
    • Academia (including research institutes) and Scientists
    International Exhibition, Startup Showcase and Business Partnering
  • The race is on!
    Winning in the era of biosimilars: Development to commercialization strategies for global markets (Panel Discussion)

    An increasing number of biologics are losing patents at a time when global cost pressures are extremely high. This is expected to result in increased uptake of biosimilar.

    India has already demonstrated leadership in the global generics market, and is now beginning to expand its biosimilars portfolio. While it is encouraging to see Indian pharma companies making an entry in the global map of biosimilars, there is a lot of room for additional growth. Pharma companies need to make the right investments and partnerships today to unlock the future market potential.

    Changing the rules of the game.
    Product supply 4.0: as the Indian pharma moves up the product value chain(Panel Discussion)

    The companies that have manufactured products the same way for decades are now being forced to reduce costs, add value and turn manufacturing and supply chain into a competitive advantage. All at a time when product categories are fast evolving along with the regulations around it and patients are becoming an inclusive part of the supply chain.

    The time is ripe for companies to look at innovative ways to become more efficient and agile at manufacturing/supply chain, and to embrace the change that is permeating the industry.

    This session will talk about:

    • What are critical factors for successful implementation of Opex in India
    • How can we deploy novel manufacturing techniques / technologies ('process automation', 'continuous manufacturing', etc.)
    • How pharma companies globally are shaping the future of supply chain and manufacturing with the advent of personalized medicine and evolving regulations?
    International Exhibition, Startup Showcase and Business Partnering
  • Can India match China in the “Bio” race?
    (Panel Discussion)
    Session sponsored by OPPI & PhRMA
    Quality is the best business plan!
    Quality by design:Is this only a regulatory mandate or a strategic must?(Panel Discussion)

    Improving quality and safety has been one of the top agendas for all Indian pharma companies for long.

    As the Indian firms plan to move up the product value chain and expand operations in International markets, achieving the desired quality standards becomes even more complex and critical.

    Quality by Design approach is based on the ideology that ‘quality cannot be tested into products; it should be built-in or should be by design.’ QbD is a way of designing and developing manufacturing processes during the product development stage to continuously maintain a predefined quality till the end of the process.

    International Exhibition, Startup Showcase and Business Partnering
  • Networking Lunch & Visit to the Exhibition
  • Make-to-order!
    Transitioning from mass therapies to mass customization (personalized medicines):Is India ready to make it Big(Panel Discussion)

    Technological and scientific advances have made it possible to move away from "one size fits all approach" to "personalized medicine". This is resulting in better diagnoses, earlier interventions, more-efficient drug therapies and customized treatment plans.

    Over 30% of New Drug Approvals by FDA in 2017 were Personalized Medicines, including the first ever CAR-T therapies that have revolutionized personalized medicine for cancer patients.Despite challenges, personalized medicine is all set to go mainstream and potentially revolutionize the healthcare industry.

    International Exhibition, Startup Showcase and Business Partnering
  • Networking Break & Visit to the Exhibition
  • Leadership 4.0
    Developing the next wave of lifesciences leaders(Panel Discussion)

    Life Sciences industry is not what it used to be, and is further expected to evolve in the coming years. The leaders have a critical role now to ensure the business is not only ready to adapt but to emerge a winner in this changing scenario.

    International Exhibition, Startup Showcase and Business Partnering
  • Networking Break & Visit to the Exhibition
  • CEO CONCLAVE(Only for Invitees)
    India for the world: exploring new horizons!
    How can India seize upside of disruption? (Panel Discussion)

    At a time of rapid technological change, markets are becoming superfluid. In this fluid environment every technology company that has access to health-related, consumer-generated information or other health data is a health care organization. At the same time, the ubiquity of mobile and peer-to-peer sharing tools are transforming consumers into super consumers. As these super consumers encounter engaging experiences in other areas of their lives, they are now demanding more of the same from their interactions with the health ecosystem. All of these changes are blurring the boundaries between industries.

    Life Sciences incumbents need to act now to ensure they continue to be relevant in the evolving market landscape.

  • Networking Dinner (Only for Invitees)
  • Keynote Addresses (Oxford Style Discussion)

    Tech companies / digital startups and pharma companies: the partnering imperative for creating future value

    Track 1: Digital Medicine and Health Tech
    Participant Profile:
    • Pharma companies
    • Biotech companies
    • CROs, CMOs, CRAMs
    • Tech companies and Deep tech experts
    • Startups
    • Medical, ethical and regulatory affairs / boards
    • Policy makers
    • Academia (including research institutes) and scientists
    • Supply chain experts
    • Public health educators and community health workers
    • Healthcare advocacy groups
    • Pharma and MedTech distributors
    International Exhibition, Startup Showcase and Business Partnering
  • The time is now!
    Life Sciences 4.0: Challenges and strategic opportunities for healthcare in India (Panel Discussion)

    Life sciences companies are facing unprecedented change. Their customers are changing, the nature of their products and sales models are changing, and they face new kinds of competitors. Epidemic of life style diseases, aging population and increasing healthcare costs are resulting in pricing pressures. The time is ripe for Indian pharma companies to create their own digital story and not fade away in the history of disruption. The next 3—4 years will be critical to move out of the traditional ways of working and embrace disruption to avoid being disrupted. But the question is how?

    This session will talk about:
    • The new LS 4.0 trends globally and in India
    • Key questions to consider while embarking on a digital journey
    • Ramifications for Indian life sciences companies’ market offerings, business models and the new capabilities needed as the disciplines of health care and technology merge to become “health technology.”
    International Exhibition, Startup Showcase and Business Partnering
  • Networking Break& Visit to the Exhibition
  • Data, the new currency!
    How can pharma leverage data for creating more value for patients(Panel Discussion)

    In the tech age, data is getting generated at several places – with the physicians, with the patients, hospitals, laboratories (diagnostics), government, wearables, LS companies, etc. As the industry moves from product-centric business models to data-centric models tied to improved health outcomes, it is critical to have the right systems that can extract value from the data.

    This session will cover:
    • What are the different new sources of data (amount of data available)
    • How data can be leveraged to generate value for patients
    • Global case studies
    International Exhibition, Startup Showcase and Business Partnering
  • Networking Lunch & Visit to the Exhibition
  • Disruptive technologies are shaping the future of business across LS value chain
    Are you ready to embrace it?(Panel Discussion)

    Digitization has already started featuring fully across all stages of the pharma value chain:

    • Digital technologies are streamlining drug discovery, personalized and accelerated clinical trial recruitment, enhanced patient engagement and automated collection of real-world evidence (using wearables and other connected devices)
    • Crowdsourced product and service ideas have started to feature in the pipelines of many companies
    • Biopharma’s supply chain is evolving into a resilient and integrated global network. Advanced analytics is helping in synchronizing the end-to-end supply chain delivering significant improvements in product flow, packing line efficiency and inventory management.
    • Product marketing is being reinvented with increasing patient centricity and changing customer expectations
    International Exhibition, Startup Showcase and Business Partnering
  • Start-Up Shark Tank